Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1261 to 1275 of 1315 results for long term conditions

  1. Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB54)

    NICE has developed a medtech innovation briefing (MIB) on the Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

  2. Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)

    NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency

  3. The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

    NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies

  4. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

  5. Accelerating innovation: How NICE is opening pathways to digital health technologies for the NHS

    Following her appearance at this year’s HETT Show, programme director Sarah Byron tells us why the government’s 10 Year Plan is a game changer for healthtech and how we’re driving the changes at NICE.

  6. Preparing for the next breakthroughs in liver disease treatments

    With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.

  7. Tackling variation in rehab for people with neurological conditions

    NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.

  8. People need support to keep weight off after treatment ends

    People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.

  9. Thousands could benefit from first immunotherapy for severe birch tree pollen allergy

    We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.

  10. 'Artificial pancreas' transforming the lives of thousands of children and young people with type 1 diabetes

    The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.

  11. NICE leads the way in approving breakthrough treatment for multiple myeloma

    People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.

  12. Fostering the digital health tech revolution

    Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.

  13. Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease

    New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.

  14. Technology recommended for people with chronic tic disorders and Tourette syndrome

    Final guidance recommends one digital therapy to help children and young people manage their condition.

  15. New guideline will help cut falls and related hospital admissions for older and at-risk people

    Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.